Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3825488 | 1.00 | GABRR1 (0.39) | GABRR1GABRR2 | |
| SCHEMBL19211598 | 1.00 | GABRR1 (0.39) | GABRR1GABRR2 | |
| SCHEMBL19211618 | 1.00 | GABRR1 (0.39) | GABRR1GABRR2 | |
| SCHEMBL19211569 | 1.00 | GABRR1 (0.39) | GABRR1GABRR2 | |
| SCHEMBL28249892 | 0.84 | IDUA (0.30) | — | |
| SCHEMBL3033289 | 0.82 | GABRR1 (0.35) | GABRR1GABRR2 | |
| SCHEMBL3276769 | 0.82 | GABRR1 (0.35) | GABRR1GABRR2 | |
| SCHEMBL3031676 | 0.82 | GABRR1 (0.35) | GABRR1GABRR2 | |
| SCHEMBL3033285 | 0.82 | GABRR1 (0.35) | GABRR1GABRR2 | |
| SCHEMBL5500989 | 0.82 | GABRR1 (0.35) | GABRR1GABRR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
| US-20210179636-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2021-06-17 | — | — | US | disclosed |
| EP-3790871-A1 | FURIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019215341-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | WO | disclosed |
| EP-3414246-A1 | ANTIBACTERIAL COMPOUNDS | Redx Pharma PLC (GB) | 2018-12-19 | — | — | EP | disclosed |
| CN-108779123-A | Fused tetracyclic compound, its composition and purposes | 泰博生物科技有限公司 | 2018-11-09 | — | — | CN | disclosed |
| WO-2017137743-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-08-17 | — | — | WO | disclosed |
| EP-1796466-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2009-09-02 | — | — | EP | disclosed |
| EP-2029612-A1 | SUBSTITUTED 1-METHYL-1H-QUINOLIN-2-ONES AND 1-METHYL-1H-1,5-NAPHTHYRIDIN-2-ONES AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2009-03-04 | — | — | EP | disclosed |
| WO-2008006648-A1 | SUBSTITUTED 1-METHYL-1H-QUINOLIN-2-ONES AND 1-METHYL-1H-1,5-NAPHTHYRIDIN-2-ONES AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| EP-1796466-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006002047-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | GABRR1 4075/4885GABRR2 4260/4885 |
| US-20210179636-A1 | ANTIBACTERIAL COMPOUNDS | OXA1L, SYMPK, TBCD | GABRR1 3451/4885GABRR2 3382/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | GABRR1 4075/4885GABRR2 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.